Valuation : Cytosorbents Corporation

Market Cap 22M 18.93M 17.81M 16.27M 30.44M 2.08B 30.52M 210M 81.68M 1.07B 82.62M 80.81M 3.43B P/E 2026 *
-1.59x
P/E 2027 * -7.78x
Enterprise Value 22M 18.93M 17.81M 16.27M 30.44M 2.08B 30.52M 210M 81.68M 1.07B 82.62M 80.81M 3.43B EV / Sales 2026 *
0.57x
EV / Sales 2027 * 0.5x
Free-Float
84.28%
Yield 2026 *
-
Yield 2027 * -
1 day+0.03%
1 week+4.32%
Current month+2.67%
1 month-7.23%
3 months-28.26%
6 months-55.68%
Current year-45.23%
1 week 0.31
Extreme 0.3115
0.47
1 month 0.3
Extreme 0.3
0.47
Current year 0.3
Extreme 0.3
0.84
1 year 0.3
Extreme 0.3
1.04
3 years 0.3
Extreme 0.3
2.66
5 years 0.3
Extreme 0.3
9.5
10 years 0.3
Extreme 0.3
14.95
Manager TitleAgeSince
Chief Executive Officer 55 2008-07-23
Director of Finance/CFO 62 2024-08-13
President 68 2020-04-27
Director TitleAgeSince
Director/Board Member 77 2011-07-24
Director/Board Member 55 2008-12-31
Director/Board Member 65 2014-11-12
Date Insider Type Main position Quantity % Market Cap. Importance
11/18/25 Free

Chief Executive Officer

100,000 0.1593%
8/8/25 Free

Chief Financial Officer

161,500 0.2579%
8/8/25 Free

Chief Executive Officer

242,000 0.3865%
Change 5-day change 1-year change 3-year change Capi.($)
+0.03%+4.32%-64.11%-86.00% 22M
-0.75%-1.35%+25.39%+10.15% 227B
-1.60%-3.89%+4.34%-21.81% 146B
-0.85%-1.58%-19.32%+18.13% 130B
+1.81%+2.05%-55.45%-10.85% 69.27B
+0.13%-0.34%+11.04%+17.70% 51.82B
+0.49%-1.32%-17.27%-14.42% 50.45B
+0.59%-1.94%+17.42%+23.75% 42.53B
-1.01%-1.28%+36.60%+45.68% 40.22B
-1.55%+1.22%+123.40%+29.54% 32.95B
Average -0.21%-0.98%+6.20%+1.19% 78.97B
Weighted average by Cap. -0.44%-1.55%+7.64%+5.98%

Financials

2026 *2027 *
Net sales 38.88M 33.46M 31.48M 28.76M 53.79M 3.67B 53.94M 372M 144M 1.88B 146M 143M 6.07B 44.16M 38M 35.75M 32.66M 61.1M 4.17B 61.27M 423M 164M 2.14B 166M 162M 6.89B
Net income -13.91M -11.97M -11.26M -10.29M -19.25M -1.31B -19.3M -133M -51.64M -674M -52.23M -51.1M -2.17B -2.77M -2.39M -2.24M -2.05M -3.83M -262M -3.85M -26.52M -10.29M -134M -10.41M -10.18M -433M
Net Debt - -
Logo Cytosorbents Corporation
CytoSorbents Corporation is engaged in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification. The Company’s blood purification technologies are based on biocompatible, highly porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. Its lead product, CytoSorb, is an extracorporeal blood purification cartridge to reduce cytokine storms in common critical illnesses that can lead to massive inflammation, organ failure and patient death. Its products also include ECOS-300CY, VetResQ, DrugSorb-ATR, and PuriFi. DrugSorb-ATR is an investigational device that uses equivalent polymer technology to CytoSorb to address a large unmet need for blood thinner reversal in cardiothoracic surgery. ECOS-300CY is used to reduce cytokines and other inflammatory mediators when used in an ex vivo organ perfusion system.
Employees
129
Date Price Change Volume
26-09-04 $0.3501 +0.03% 462,305
26-09-03 $0.3500 -8.81% 768,321
26-09-02 $0.3838 +13.55% 5,798,571
26-09-01 $0.3380 -0.88% 62,800
26-08-31 $0.3410 +1.61% 111,597
Trader
Investor
-
Global
-
Quality
-
ESG MSCI
-
Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
1
Last Close Price
0.3501USD
Average target price
2.375USD
Spread / Average Target
+578.38%

Quarterly revenue - Rate of surprise

  1. Stock Market
  2. Stocks
  3. CTSO Stock